- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02844738
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Shoulder
Safety and Effectiveness of Autologous Regenerative Cell Therapy on Pain and Inflammation Associated With Osteoarthritis of the Shoulder
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective open-label clinical study of 50 patients to determine safety and treatment potential of autologous cell therapy for pain and inflammation associated with Osteoarthritis of the shoulder. Follow-up will consist of a larger sample including 4,000 patients.
Patients will be treated for Osteoarthritis (OA) of the shoulder due to degeneration or chronic injury. They will be treated with autologous Stromed obtained by the Adipose Ultrasonic Cell Recovery Unit (AUCRU) and Platelet Rich Plasma (PRP) processed by the RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints. Patient outcomes will be tracked with laboratory tests for inflammation markers, the DASH and SPADI questionnaires and a follow up MRI at various endpoints to 6 months. SF-36 forms (a quality of life measure) and numerical ratings scales (NRS) will also be used to assess safety and efficacy of treatment, as well as any reduction in patient medication and/or delay in pending shoulder planning/replacement therapy.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Michael P Hutchinson, DVM
- Phone Number: 412-503-3788
- Email: drmike@vivatechusa.com
Study Contact Backup
- Name: Scott M Herkes, MBA
- Phone Number: 855-984-8287
- Email: scott.herkes@gmail.com
Study Locations
-
-
Pennsylvania
-
Grove City, Pennsylvania, United States, 16127
- Recruiting
- VivaTech International, Inc.
-
Principal Investigator:
- Mark LoDico, MD
-
Contact:
- Michael Hutchinson, DVM
- Phone Number: 412-503-3788
- Email: drmike@vivatechusa.com
-
Contact:
- Scott M Herkes, MBA
- Phone Number: 855-984-8287
- Email: scott.herkes@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with indication of Osteoarthritis. Can be from degeneration or chronic injury.
- Patients range from 18-90 years of age.
- Patients must be able to comply with treatment plan, laboratory tests and periodic interviews.
- Patients with adequate renal function, Creatinine ≤ 1.5 mg/dl.
- Patients with adequate cardiac and respiratory function.
- Patients with adequate blood coagulation activity, PT(INR) < 1.5, APTT
- Patients must have adequate immune system function, with no known immunodeficiency disease.
- Greater than 6 months shoulder pain with the index side (left or right shoulder).
Exclusion Criteria:
- Neoplastic cancer within 5 years prior to screening, except for cutaneous basal cell or squamous cell cancer resolved by excision
- Presence of clinically significant acute or unstable cardiovascular, cerebrovascular (stroke)..
- Diagnosis of a transient ischemic attack in the 6 months prior to screening.
- Patients infected with hepatitis B, C or HIV.
- Patients with Body Mass Index (BMI) > 40kg/m2
- Presence of active infection.
- Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the investigator would render a patient unsuitable to participate in the study.
Conditions/therapies/factors which could confound or interfere with the evaluation of pain/mobility including, but not limited to:
- Treatments with strong opioid drugs in the previous 4 weeks for other pain rather than shoulder osteoarthritis
- Corticosteroid injection at treatment site within 1 month
- Consistent use of NSAIDs within 48 hours of procedure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: StroMed + platelet rich plasma (PRP)
Because no enzymes or drugs are added with this mechanical process, the resulting (StroMed) cell concentrate still contains the extra-cellular matrix.
In addition, the cells have not been altered by manipulation with enzymes or culturing.
This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added.
Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to affected joint.
|
Patients will be treated with autologous StroMed obtained by the Adipose Ultrasonic Cell Recovery Unit and Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints at the time of initial treatment.
Thereafter the affected joints will be treated as direct injections to the joint with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product.
Day 0 [StroMed + platelet rich plasma (PRP)], Days 7 and 14 [PRP]
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change is being assessed for the DASH Survey (Disabilities of the Arm, Shoulder, Hand
Time Frame: 0,2,6 months
|
Disabilities of the Arm, Shoulder, and Hand
|
0,2,6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change is being assessed by MRI of afflicted joint
Time Frame: 0 and (6 months optional)
|
Looking for cartilage regrowth via MRI
|
0 and (6 months optional)
|
Change is being assessed for the SPADI Survey (Shoulder Pain and Disability Index)
Time Frame: 0,2,6 Months
|
Shoulder Pain and Disability Index
|
0,2,6 Months
|
Change is being assessed for the SF36 Survey (Short Form Health Survey)
Time Frame: 0,2,6 Months
|
Short Form Health Survey
|
0,2,6 Months
|
Change is being assessed for the NRS Survey (Numerical Rating Scale for Pain)
Time Frame: 0,2,6 Months
|
Numerical Rating Scale for Pain
|
0,2,6 Months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mark LoDico, MD, Advanced Regenerative Medicine
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
-  IRCM-2016-113
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis
-
Sanford HealthActive, not recruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder Osteoarthritis | Ankle Osteoarthritis | Wrist OsteoarthritisUnited States
-
University of EdinburghHospital for Special Surgery, New YorkRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited Kingdom
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
Hospital for Special Surgery, New YorkRoyal Infirmary of EdinburghRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited States, United Kingdom
-
Ottawa Hospital Research InstituteNot yet recruitingKnee Osteoarthritis | Hip Osteoarthritis
-
University Hospital, LilleCompleted
-
Massachusetts General HospitalNewton-Wellesley Hospital; The New England Baptist HospitalCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
West Virginia UniversityAgency for Healthcare Research and Quality (AHRQ)WithdrawnKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
Diakonhjemmet HospitalThe Research Council of NorwayCompletedKnee Osteoarthritis | Hip OsteoarthritisNorway
Clinical Trials on [StroMed + platelet rich plasma (PRP)]
-
VivaTech International, Inc.RecruitingOsteoarthritisUnited States
-
VivaTech International, Inc.RecruitingOsteoarthritisUnited States
-
Stanford UniversityPartnership for Clean CompetitionCompletedRheumatic Diseases | TendinopathyUnited States
-
Damascus UniversityCompletedBone ResorptionSyrian Arab Republic
-
Sutherland Medical CenterActive, not recruitingRotator Cuff Tears | Rotator Cuff TendinosisPoland
-
University of Colorado, DenverTerumo BCTCompletedOsteochondritis DissecansUnited States
-
Germans Trias i Pujol HospitalCompletedEvaluation of the Efficacy of Platelet-rich Plasma (PRP) on Advanced Endoscopic Resection TechniquesEndoscopic Submucosal Dissection | Platelet-rich Plasma | Endoscopic Mucosal ResectionSpain
-
Genesis Athens ClinicNational and Kapodistrian University of AthensRecruitingMenopause, Premature | Menopausal Syndrome | Premature Ovarian Failure | Ovarian Failure, Premature | Menopause Related ConditionsGreece
-
University of Kansas Medical CenterUnknownTympanic Membrane PerforationUnited States
-
Cairo UniversityFayoum UniversityTerminated